DFMO inhibition of neuroblastoma tumorigenesis
Cancer Medicine · 2024-05 · 13 (9)
DOI: 10.1002/cam4.7207 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 30.04.2024. Verfasst von Divya Gandra und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Penn State Health Children's Hospital, Hershey, Pennsylvania, USA. Hauptthemen laut MEDLINE: Neuroblastoma, Apoptosis, Eflornithine, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beat Childhood Cancer Foundation, Ethan's Rodeo, Meryl and Charles Witmer Foundation, Brooke's Blossoming Hope Foundation.
Abstract (Originalsprache)
Background
Most high‐risk neuroblastoma patients who relapse succumb to disease despite the existing therapy. We recently reported increased event‐free and overall survival in neuroblastoma patients receiving difluoromethylornithine (DFMO) during maintenance therapy. The effect of DFMO on cellular processes associated with neuroblastoma tumorigenesis needs further elucidation. Previous studies have shown cytotoxicity with IC50 values >5–15 mM, these doses are physiologically unattainable in patients, prompting further mechanistic studies at therapeutic doses.
Methods
We characterized the effect of DFMO on cell viability, cell cycle, apoptosis, neurosphere formation, and protein expression in vitro using five established neuroblastoma cell lines (BE2C, CHLA‐90, SHSY5Y, SMS‐KCNR, and NGP) at clinically relevant doses of 0, 50, 100, 500, 1000, and 2500 μM. Limiting Dilution studies of tumor formation in murine models were performed. Statistical analysis was done using GraphPad and the level of significance set at p = 0.05.
Results
There was not a significant loss of cell viability or gain of apoptotic activity in the in vitro assays ( p > 0.05). DFMO treatment initiated G1 to S phase cell cycle arrest. There was a dose‐dependent decrease in frequency and size of neurospheres and a dose‐dependent increase in beta‐galactosidase activity in all cell lines. Tumor formation was decreased in xenografts both with DFMO‐pretreated cells and in mice treated with DFMO.
Conclusion
DFMO treatment is cytostatic at physiologically relevant doses and inhibits tumor initiation and progression in mice. This study suggests that DFMO, inhibits neuroblastoma by targeting cellular processes integral to neuroblastoma tumorigenesis at clinically relevant doses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Penn State Health Children's Hospital, Hershey, Pennsylvania, USA.
- Department of Pediatrics, Levine Children's Hospital, Charlotte, North Carolina, USA.
- Department of Medicine, Levine Cancer Institute, Charlotte, North Carolina, USA.
ORCID-Profile: David M Foureau, Giselle L Saulnier Sholler
Förderung
- Beat Childhood Cancer Foundation
- Ethan's Rodeo, Meryl and Charles Witmer Foundation
- Brooke's Blossoming Hope Foundation
Zitieren
APA
Gandra, D., Mulama, D. H., Foureau, D. M., McKinney, K. Q., Kim, E., Smith, K., Haw, J., Nagulapally, A., & Saulnier Sholler, G. L. (2024). DFMO inhibition of neuroblastoma tumorigenesis. Cancer Medicine, 13(9). https://doi.org/10.1002/cam4.7207
Vancouver
Gandra D, Mulama DH, Foureau DM, McKinney KQ, Kim E, Smith K, et al. DFMO inhibition of neuroblastoma tumorigenesis. Cancer Medicine. 2024;13(9). doi:10.1002/cam4.7207
BibTeX
@article{Gandra2024,
author = {Gandra, Divya and Mulama, David H and Foureau, David M and McKinney, Kimberly Q and Kim, Elizabeth and Smith, Kaitlyn and Haw, Jason and Nagulapally, Abhinav and Saulnier Sholler, Giselle L},
title = {DFMO inhibition of neuroblastoma tumorigenesis},
journal = {Cancer Medicine},
year = {2024},
volume = {13},
number = {9},
doi = {10.1002/cam4.7207}
}
EUVIMED